List of Clinical Trials

Anal Squamous Cell Carcinoma - INCMGA 0012-303

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)

Urothelial Cancer - SGN22E-002

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Breast Cancer - 3379428

Phase 1/2, trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Breast Cancer - FLEX Registry

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

Triple Negative Breast Cancer - D933LC00001

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Breast Cancer - GO42784

A Phase 3, Randomized, Open Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant compared with Physicians choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Triple Negative Breast Cancer - D8534C00001

A Phase 3, double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (Palbociclib or Abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study

KRAS G12C metastatic Colorectal Cancer - 849-010

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Esophageal Squamous Cell Carcinoma - CIBI308A301

A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)

Esophageal Squamous Cell Carcinoma - PRS 343 PCS_09_20

A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(

Ovarian, Peritoneal, Fallopian - IMGN853-0416

Phase 3, Study of Mirvetuximab Soravtansine vs Investigators' Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Ovarian - VS-6766-201 | GOG 3052

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer

Ovarian, Peritoneal, Fallopian - LAE002INT2001

An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer

Ovarian, Peritoneal, Fallopian - CBYL719K12301

A Phase 3, randomized (1:1) open-label active-controlled study to assess the efficacy and safety of alpelisib in combination with Olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

Squamous Cell Carcinoma - CPI-006-001

A Phase 1/1b Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers

Multiple Myeloma - 54767414MMY3021

A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Chronic Lymphocytic Leukemia (CLL) - LOXO-BTK-20020 / J2N-OX-JZNN

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Islas-Ohlmayer)

Chronic Myeloid Leukemia (CML) - CABL001J12301

A Phase 3 Multi-center, open-label, randomized study of oral Asciminib versus Investigator selected TKI in patients with newly diagnosed Ph+ CML in chronic phase

Chronic Myeloid Leukemia (CML) - CABL001AUS04

A Phase 3b, open label, multi-center study of Asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase with and without T315i mutation

Small Cell Lung Cancer - 20200491

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Non Small Cell Lung Cancer - 849-007

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Non Small Cell Lung Cancer - 516-005

A Phase 3, Randomized Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Non Small Cell Lung Cancer - CA209-73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer - SGN35-033

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid tumors after progression on prior PD-1 inhibitor treatment (Waterhouse)

Non Small Cell Lung Cancer - 61186372NSC3001

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer - 20381

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Hodgkin's Lymphoma - SGN35-015

a Phase 2, Therapeutic. Brentuximab Vedotin provided. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults age 60 and Above

Follicular Lymphoma - EZH-302

A Phase 1b/3 double-blind, randomized, active-controlled 3-stage, biomarker, adaptive study of Tazemetostat or placebo in combination with Lenalidomide plus Rituximab in subjects with relapsed/refractory Follicular Lymphoma

Follicular Lymphoma - GO41036

A Phase 1a/1b, Open-label, multicenter study evaluating the safety of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma

Peripheral T-Cell Lymphoma - SGN35-032

A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

Diffuse Large B-Cell Lymphoma - SGN35-031

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma - ADCT-402-203

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma - MOR208C310

A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma

Previous CAR-T Cell Therapy - GC-LTFU-001

Long-term follow-up protocol for subjects treated with gene-modified T-cells

Small Lymphocytic Lymphoma (SLL) - LOXO-BTK-20020 / J2N-OX-JZNN

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Mantle Cell Lymphoma - LOXO-BTK-20019

A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Myelodysplastic Syndrome - M15-954

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA)

Myelodysplastic Syndrome - KCP-8302-801

A Phase 1/2 Open-Label Study of the Safety, Tolerability, and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) compound Eltanexor in Patients with relapsed or refractory MDS

Myelofibrosis - M16-191

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis

Myelofibrosis - XPORT-MF-035

A Phase 2 Open-Label, multicenter study to evaluate safety and efficacy of single agent Selinexor versus treatment of physicians choice in patients with previously treated myelofibrosis

Multiple Myeloma - 207495

A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone i9n Participants with Relapsed/Refractory Multiple Myeloma (Faber)

Multiple Myeloma - 54767414MMY3021

A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Pancreatic - CBP 21-01

A Phase 2 Multicenter, randomized, parallel group study to establish the efficacy and safety of combinations of CBP501 ,cisplatin, and nivolumab for >/= 3rd line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3

Metastatic Castration-resistant Prostate Cancer - D361BC00001

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterized by PTEN deficiency

Metastatic Castration-sensitive Prostate Cancer - 67652000PCR3002

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Metastatic Prostate Cancer - CA002-009

A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer

Metastatic Cutaneous Melanoma - SGN35-033

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid tumors after progression on prior PD-1 inhibitor treatment

Basal Cell Carcinoma - CX-4945-07

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma

Melanoma - XPORT-MEL-033

A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination with Pembrolizumab in Newly Diagnosed or Recurrent Advanced melanoma

Solid Tumor with KRAS G12C Mutation - 849-001

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Advanced and unresectable or metastatic solid malignancy (various mutations) - BO41932

Tumor-agnostic precision immuno-oncology and somatic targeting rational for you (TAPISTRY) phase II platform trial